The Phases of Clinical Trials: From Preclinical Studies to Post-market Surveillance
Main Article Content
Abstract
Clinical trials are basic within the improvement and assessment of therapeutic intercessions, including unmistakable stages to guarantee safety, efficacy, and quality. The method starts with preclinical considerations, conducted in research facilities and on creature models, to survey preparatory security and natural action. On the off chance that comes about are promising, Stage I trials commence, including a small bunch of solid volunteers or patients to assess security, measurement, and pharmacokinetics. Stage II trials extend the member pool, centering on adequacy and side impact profiling with a focus on the populace. Victory in Stage II leads to Stage III trials, large-scale considers planned to affirm helpful adequacy, screen antagonistic responses, and compare the intercession with standard medicines. These trials frequently include assorted populaces and numerous centers, producing strong data for regulatory endorsement. After the effective completion of Stage III, administrative offices just like the FDA or EMA audit the discoveries to give advertising authorization. Be that as it may, the assessment does not conclusion here; Stage IV, or post-market observation, starts once the mediation is accessible to the open. This phase monitors long-term impacts, uncommon unfavorable occasions, and real-world viability, contributing to the continuous risk-benefit investigation. Each stage could be a fastidiously arranged step, represented by moral contemplations and administrative systems, guaranteeing that restorative headways are interpreted into secure and successful medications for patients.
Downloads
Article Details
Copyright (c) 2024 Kumar RD.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Lemmens T, Gibson S. Decreasing the data deficit: improving post-market surveillance in pharmaceutical regulation. McGill Law J. 2014. Available from: https://lawjournal.mcgill.ca/article/decreasing-the-data-deficit-improving-post-market-surveillance-in-pharmaceutical-regulation/
Patel V. Pharmaceutical science- quality, regulations, and drug development. Cipher Publisher; 2024.
Latha BD, More N, Kapusetti G, Tekade RK. Chapter 23 - Clinical trial design for medical devices "Emerging Pharmaceuticals." In: Tekade RK, editor. The future of pharmaceutical product development and research. Academic Press; 2020;531-50. Available from: http://dx.doi.org/10.1016/B978-0-12-814455-8.00023-2
Sethi R, Popli H. A comparative study of marketing authorization of drug eluting coronary stents (DES) in India and developed countries (USA & EU). Appl Clin Res Clin Trials Regul Aff. 2017;4(4):166. Available from: http://dx.doi.org/10.2174/2213476X04666171115155031
https://ijphr.com/index.php/ijphr/index
https://wjpr.s3.ap-south-1.amazonaws.com/article_issue/1561011381.pdf/
Deore AB, Jayprabha RD, Dhumane R, Wagh R, Sonawane R. The stages of drug discovery and development process. Asian J Pharm Res Dev. 2019;7(6):62-67. Available from: https://doi.org/10.22270/ajprd.v7i6.616
Tompkins TA, Xu X, Ahmarani J. A comprehensive review of post-market clinical studies performed in adults with an Asian probiotic formulation. Benef Microbes. 2010;1(1):93-106. Available from: https://doi.org/10.3920/bm2008.1005
Luff MK, Sedrakyan A, Ansari SA, Siddiqui A, Liebeskind DS. Postmarket surveillance of neuroendovascular devices. Stroke Vasc Interv Neurol. 2024;4:e001081. Available from: http://dx.doi.org/10.1161/SVIN.123.001081
Kumar R, Keserwani N, Goyal PK. Safety perspectives of medicinal products. In: Global regulations of medicinal, pharmaceutical, and food products. CRC Press; 2024.
KD SS, Joga R, Srivastava S, Nagpal K, Dhamija I, Grover P, et al. Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. Eur J Pharm Biopharm. 2024;201:114361. Available from: https://doi.org/10.1016/j.ejpb.2024.114361
Mourya AS, Pandey RK. A study on factors attributed to failure of pharmaceutical products. Pharm Sci & Tech. 2024;3:12-21. Available from: https://doi.org/10.5281/zenodo.10976869
Aranda J, Dobrzynska A, Rosario-Lozano MP, Rejón-Parrilla JC, Epstein D, Blasco-Amaro JA. Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2024:1-15. Available from: https://doi.org/10.1080/14737167.2024.2431234
Shelke S. Navigating drug regulatory affairs: An analytical review of compliance in the pharmaceutical industry. J Drug Deliv Biotherapeutics. 2024;1(02):1-12. Available from: https://doi.org/10.61920/jddb.v1i02.144
Manita, Aakash D, Vikram, Rana AC, Sharma PC. Regulation and clinical investigation of medical devices in the European Union. J Clin Pharmacol. 2019;6:163-181. Available from: https://doi.org/10.2174/2213476X06666190821095407
Sharma P, Jhawat V, Singh J, Dutt R. Knowledge and awareness of emerging cancer therapies and their regulations among budding scientists in India: A survey. Curr Cancer Ther Rev. 2024;20:595-600. Available from: http://dx.doi.org/10.2174/0115733947268695231116100736
Sparrow E, Torvaldsen S, Newall AT, Wood JG, Sheikh M, Kieny MP. Recent advances in the development of monoclonal antibodies for rabies post-exposure prophylaxis: A review of the current status of the clinical development pipeline. Vaccine. 2019;37:A132-A139. Available from: https://doi.org/10.1016/j.vaccine.2018.11.004
Tuyishime HS. Drug development and discovery (D3): An overview of the drug discovery process and its development. ScienceOpen Posters. 2023. Available from: https://orcid.org/0000-0001-6372-0556
Janjal VS, Dhamodkar SR, Jadhao YP, Manmode SB, Pawar AK, Khandelwal HR. Recent drug regulatory affair and CTD module progress review for submission of pharmaceutical product. GSC Biol Pharm Sci. 2021;16(03):200–221. Available from: https://doi.org/10.30574/gscbps.2021.16.3.0279
Zhang BL, Bianco RW, Schoen FJ. Preclinical assessment of cardiac valve substitutes: Current status and considerations for engineered tissue heart valves. Front Cardiovasc Med. 2019. Available from: https://doi.org/10.3389/fcvm.2019.00072
Mohanty S, Rashid MHAI, Mridul M, Mohanty C, Swayamsiddha S. Application of artificial intelligence in COVID-19 drug repurposing. Diabetes Metab Syndr Clin Res Rev. 2020;14:1027-1031. Available from: https://doi.org/10.1016/j.dsx.2020.06.068
Jordan CJ, Xi Z-X. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;13:671-683. Available from: https://doi.org/10.1080/17460441.2018.1458090
de Sa A. A policy analysis to inform options for medical device regulation and post-market surveillance in the Canadian context. Available from: https://summit.sfu.ca/item/18475
What differentiates clinical trial statistics from preclinical methods and why robust approaches matter. Nat Commun. 2024;15:7035. Available from: https://www.nature.com/articles/s41467-024-51486-4
Øvrebø Ø, Perale G, Wojciechowski JP, Echalier C, Jeffers JRT, Stevens MM, et al. Design and clinical application of injectable hydrogels for musculoskeletal therapy. Bioengineering Transl Med. 2022;7:e10295. Available from: https://doi.org/10.1002/btm2.10295
Badria FA. Drug repurposing: Hypothesis, molecular aspects, and therapeutic applications. In: BoD – Books on Demand; 2020. Available from: https://www.intechopen.com/books/9086
Ramdasani U, Vinzuda G, Tanwar S, Gupta R, Guizani M. DuBloQ: Blockchain and Q-learning based drug discovery in Healthcare 4.0. In: 2022 International Wireless Communications and Mobile Computing (IWCMC). 2022. Available from: https://doi.org/10.1109/IWCMC55113.2022.9824216
http://ww12.pressinspire.com/JDDB/1/article/view/111?usid=15&utid=31614837028> accessed 11 December 2024
Sharma S, Chakraborty M, Yadav D, Dhullap A, Singh R, Verma RK, et al. Strategic developments in polymer-functionalized liposomes for targeted colon cancer therapy: An updated review of clinical trial data and future horizons. Biomacromolecules. 2024;25:5650-5669. Available from: https://doi.org/10.1021/acs.biomac.4c00847
Strategies for Searching IEEE Xplore. Available from: https://bibliotecnica.upc.edu/sites/default/files/pagines_generals/investigadors/ieee_xplore.pdf
Silber S. Paclitaxel-eluting stents: Are they all equal?: An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol. 2003;16:485-490. Available from: https://onlinelibrary.wiley.com/doi/10.1046/j.1540-8183.2003.01065.x
Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:58683.A1. Available from: https://www.ahajournals.org/doi/10.1161/01.CIR.0000047700.58683.A1
Hurson CJ, Butler SJ, Keating DT, Murray DW, Sadlier DM, O'Byrne JM, et al. Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis. BMC Musculoskelet Disord. 2007;8:12. Available from: https://link.springer.com/article/10.1186/1471-2474-8-12
Malkawi AK, Masood A, Shinwari Z, Jacob M, Benabdelkamel H, Matic G, et al. Proteomic analysis of morphologically changed tissues after prolonged dexamethasone treatment. Int J Mol Sci. 2019;20(13):3122. Available from: https://doi.org/10.3390/ijms20133122
Armitage P. The search for optimality in clinical trials. Int Stat Rev. 1985;53:15-24. Available from: https://www.jstor.org/stable/1402871
Nahum-Shani I, Qian M, Almirall D, Pelham D, Gnagy WE, Fabiano B, et al. Experimental design and primary data analysis methods for comparing adaptive interventions. Psychol Methods. 2012;17:457-477. Available from: https://psycnet.apa.org/doi/10.1037/a0029372
Tang HH, Lee YY, Gero JS. Comparing collaborative co-located and distributed design processes in digital and traditional sketching environments: A protocol study using the function–behaviour–structure coding scheme. Design Stud. 2011;32:1-29. Available from: https://www.sciencedirect.com/science/article/pii/S0142694X10000475
Rocha-García D, Guerra-Contreras A, Rosales-Mendoza S, Palestino G. Role of porous silicon/hydrogel composites on drug delivery. Mesoporous Biomaterials. 2016;3. Available from: https://doi.org/10.1515/mesbi-2016-0011
Rezaee ME, LeRoy L, White A, Oppenheim E, Carlson K, Wasserman M. Understanding the high prevalence of low-prevalence chronic disease combinations: Databases and methods for research. ASPE Reports. 2013. Available from: https://aspe.hhs.gov/reports/understanding-high-prevalence-low-prevalence-chronic-disease-combinations-databases-methods-research-0